xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

566

INTERNATIONAL CONSENSUS ON OLFACTION

TABLE IX-12 Evidence for CRSsNP-related olfactory loss management with topical corticosteroid therapy

Clinical end point

Study

Year 2019

LOE Study design

Study groups CRSwNPand CRSsNP (n = 187) FPNS200 μ g oncedaily Oral clar ithromycin 250mgonce daily CRS with and without polyps post-ESS (N = 44) 12 months of follow-up MFNSnasal irrigation 2 mg (n = 21) MFNS2mg (n = 23) CRSsNP (n = 43) MFNS200 μ g oncedaily × 12weeks Oral clar ithromycin 250-mg tablet oncedaily × 12weeks Data collection point: week 4, spray 12 week courseof: FPNS400 μ g twice daily (n = 10) Placebo (n = 10) CRS (n = 167) Budesonide NS 128 μ g twice daily × 20 weeks Placebo × 20 weeks week8, week12 CRSsNP (N = 20) Bidirectional

Conclusions Compared with baseline, both groups demonstrated

VAS (0–10) Data collection points: month 1,month3, month 6, and month12

Zeng

2

RCT

et al 1387

improvement in VASbut no significant difference between groups

Harvey

2018

2

Double-blind RCT

VAS (0–100)

No significant

et al 1407

different between spray and irrigation

Compared with

Subjective

Zeng

2011

2

RCT

et al 1427

baseline, only the mometasone group demonstrated significant improvement at week4only improvement in the clarithromycin group

symptom score (0–3) Data collection points: week 4,week8, week 12

No significant

Hansen

2010

2

RCT

Subjective

Compared with

et al 1428

symptom score (0–3) Data collection

placebo, the FP group demonstrated significantly greater improvement in subjective symptom score at week 12

point: week 12

Compared with placebo, the

Lund

Subjective

2004

2

RCT

et al 1429

symptom score (0–3) (amandpm) Data collection: week20

budesonide group demonstrated significantly greater improvement in subjective symptom

score in the am only at week 20

(Continues)